Phatsawee Jansook

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1012201/publications.pdf

Version: 2024-02-01

279798 206112 2,466 51 23 48 citations g-index h-index papers 53 53 53 2803 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. International Journal of Pharmaceutics, 2018, 535, 272-284.	5.2	518
2	Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes. Molecules, 2018, 23, 1161.	3.8	407
3	Self-assembled cyclodextrin aggregates and nanoparticles. International Journal of Pharmaceutics, 2010, 387, 199-208.	5 . 2	274
4	Cyclodextrins as solubilizers: Formation of complex aggregates. Journal of Pharmaceutical Sciences, 2010, 99, 719-729.	3.3	107
5	Topical Dexamethasone-Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema. , 2011, 52, 7944.		90
6	Carvedilol: Solubilization and Cyclodextrin Complexation: A Technical Note. AAPS PharmSciTech, 2008, 9, 425-430.	3.3	82
7	CDs as solubilizers: Effects of excipients and competing drugs. International Journal of Pharmaceutics, 2009, 379, 32-40.	5.2	77
8	Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: Formulation of dorzolamide eye drop microparticle suspension. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 208-214.	4.3	65
9	Self-assembly of cyclodextrin complexes: Aggregation of hydrocortisone/cyclodextrin complexes. International Journal of Pharmaceutics, 2011, 407, 174-183.	5.2	63
10	Topical drug delivery to the eye: dorzolamide. Acta Ophthalmologica, 2012, 90, 603-608.	1.1	61
11	Effect of self-aggregation of \hat{l}^3 -cyclodextrin on drug solubilization. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2010, 68, 229-236.	1.6	46
12	Amphotericin B loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): physicochemical and solid-solution state characterizations. Drug Development and Industrial Pharmacy, 2019, 45, 560-567.	2.0	40
13	Development of a cyclodextrin-based aqueous cyclosporin A eye drop formulations. International Journal of Pharmaceutics, 2015, 493, 86-95.	5.2	39
14	yCD/HPyCD Mixtures as Solubilizer: Solid-State Characterization and Sample Dexamethasone Eye Drop Suspension. Journal of Pharmacy and Pharmaceutical Sciences, 2010, 13, 336.	2.1	38
15	Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations. Drug Development and Industrial Pharmacy, 2018, 44, 1693-1700.	2.0	35
16	Cyclodextrin–poloxamer aggregates as nanocarriers in eye drop formulations: dexamethasone and amphotericin B. Drug Development and Industrial Pharmacy, 2016, 42, 1446-1454.	2.0	34
17	Topical drug delivery to the posterior segment of the eye: Dexamethasone concentrations in various eye tissues after topical administration for up to 15 days to rabbits. Journal of Drug Delivery Science and Technology, 2018, 45, 449-454.	3.0	34
18	Pharmacokinetics of a new, nasal formulation of naloxone. European Journal of Clinical Pharmacology, 2017, 73, 555-562.	1.9	31

#	Article	IF	CITATIONS
19	Effect of \hat{I}^3 -cyclodextrin on solubilization and complexation of irbesartan: Influence of pH and excipients. International Journal of Pharmaceutics, 2014, 474, 80-90.	5.2	29
20	The investigation of binary and ternary sulfobutylether-β-cyclodextrin inclusion complexes with asiaticoside in solution and in solid state. Carbohydrate Research, 2020, 498, 108190.	2.3	27
21	Cyclodextrin-based telmisartan ophthalmic suspension: Formulation development for water-insoluble drugs. International Journal of Pharmaceutics, 2016, 507, 21-31.	5.2	26
22	î³CD/HPî³CD: Synergistic solubilization. International Journal of Pharmaceutics, 2008, 363, 217-219.	5.2	25
23	Development of eye drops containing antihypertensive drugs: formulation of aqueous irbesartan/l³CD eye drops. Pharmaceutical Development and Technology, 2015, 20, 626-632.	2.4	25
24	Development of celecoxib eye drop solution and microsuspension: A comparative investigation of binary and ternary cyclodextrin complexes. Carbohydrate Polymers, 2019, 225, 115209.	10.2	25
25	\hat{l}^3 -Cyclodextrin Nanoparticle Eye Drops with Dorzolamide: Effect on Intraocular Pressure in Man. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 35-41.	1.4	24
26	Self-assembled \hat{l}^3 -cyclodextrin as nanocarriers for enhanced ocular drug bioavailability. International Journal of Pharmaceutics, 2022, 618, 121654.	5.2	18
27	Drug loading in cyclodextrin polymers: dexamethasone model drug. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2011, 69, 377-382.	1.6	17
28	Cyclodextrin solubilization of celecoxib: solid and solution state characterization. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2018, 90, 75-88.	1.6	17
29	Development of amphotericin B nanosuspensions for fungal keratitis therapy: effect of self-assembled γ-cyclodextrin. Journal of Pharmaceutical Investigation, 2020, 50, 513-525.	5.3	17
30	Development of in situ gel containing asiaticoside/cyclodextrin complexes. Evaluation in culture human periodontal ligament cells (HPLDCs). International Journal of Pharmaceutics, 2020, 586, 119589.	5.2	17
31	Evaluation of \hat{I}^3 -cyclodextrin effect on permeation of lipophilic drugs: application of cellophane/fused octanol membrane. Pharmaceutical Development and Technology, 2017, 22, 562-570.	2.4	14
32	Physicochemical and Stability Evaluation of Topical Niosomal Encapsulating Fosinopril/ \hat{I}^3 -Cyclodextrin Complex for Ocular Delivery. Pharmaceutics, 2022, 14, 1147.	4.5	14
33	Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure. Acta Ophthalmologica, 2021, 99, 376-382.	1.1	13
34	Aqueous solubility of kinase inhibitors: I the effect of hydrophilic polymers on their \hat{l}^3 -cyclodextrin solubilization. Journal of Drug Delivery Science and Technology, 2020, 55, 101462.	3.0	12
35	Cyclodextrin-based formulation of carbonic anhydrase inhibitors for ocular delivery – A review. International Journal of Pharmaceutics, 2021, 606, 120955.	5.2	12
36	Formation and stability assessment of self-assembled nanoparticles from large Mw chitosan and sulfobutylether-Î ² -cyclodextrin. Journal of Drug Delivery Science and Technology, 2015, 30, 478-485.	3.0	11

#	Article	IF	Citations
37	Topical drug delivery to the posterior segment of the eye: The effect of benzalkonium chloride on topical dexamethasone penetration into the eye in vivo. Journal of Drug Delivery Science and Technology, 2018, 48, 125-127.	3.0	11
38	Antifungal activity of econazole nitrate/cyclodextrin complex: Effect of pH and formation of complex aggregates. International Journal of Pharmaceutics, 2020, 574, 118896.	5.2	10
39	Solubilization and in vitro permeation of dovitinib/cyclodextrin complexes and their aggregates. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2020, 97, 195-203.	1.6	8
40	Bio-Distribution and Pharmacokinetics of Topically Administered \hat{I}^3 -Cyclodextrin Based Eye Drops in Rabbits. Pharmaceuticals, 2021, 14, 480.	3.8	8
41	Self-assembly of cyclodextrin complexes: detection, obstacles and benefits. Die Pharmazie, 2020, 75, 307-312.	0.5	8
42	Aqueous solubility of kinase inhibitors: II the effect of hexadimethrine bromide on the dovitinib/γ-cyclodextrin complexation. Journal of Drug Delivery Science and Technology, 2020, 55, 101463.	3.0	6
43	Cyclodextrin-based Pickering nanoemulsions containing amphotericin B: Part II. Formulation, antifungal activity, and chemical stability. Journal of Drug Delivery Science and Technology, 2022, 69, 103174.	3.0	6
44	Effect of porcine pancreatic \hat{l}_{\pm} -amylase on dexamethasone release from aqueous solution containing natural \hat{l}_{\pm} -cyclodextrin. International Journal of Pharmaceutics, 2020, 585, 119452.	5.2	5
45	Effect of salt formation on Î ³ -cyclodextrin solubilization of irbesartan and candesartan and the chemical stability of their ternary complexes. Journal of Drug Delivery Science and Technology, 2022, 67, 102980.	3.0	4
46	Surface activity and self-aggregation ability of three cationic quaternized aminocalix [4] arenes. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2014, 79, 473-483.	1.6	3
47	Aqueous solubility of kinase inhibitors: III the effect of acidic counter ion on the dovitinib/ \hat{l}^3 -cyclodextrin complexation. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2020, 98, 57-67.	1.6	3
48	Cyclodextrin-based Pickering nanoemulsions containing amphotericin B: Part I. evaluation of oil/cyclodextrin and amphotericin B/cyclodextrin inclusion complexes. Journal of Drug Delivery Science and Technology, 2022, 68, 103118.	3.0	3
49	Solubility and stability of cediranib maleate. Journal of Drug Delivery Science and Technology, 2021, 62, 102359.	3.0	2
50	Angiotensin converting enzyme inhibitors/cyclodextrin inclusion complexes: solution and solid-state characterizations and their thermal stability. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2022, 102, 347-358.	1.6	2
51	Effect of Soluplus $\langle \sup \rangle \hat{A}^{\otimes} \langle \sup \rangle$ on \hat{I}^3 -cyclodextrin solubilization of irbesartan and candesartan and their nanoaggregates formation. Pharmaceutical Development and Technology, 2022, 27, 9-18.	2.4	0